Related Experiment Video
Updated: Aug 23, 2026
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Duration of immunosuppressive treatment for chronic graft-versus-host disease
Betty L Stewart1, Barry Storer, Jan Storek
1Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA.
Insights
Longer immunosuppressive therapy for chronic graft-versus-host disease (GVHD) is linked to specific patient and donor factors, including peripheral blood stem cells and HLA mismatching. Some factors prolonging treatment also increase non-relapse mortality risk.
Area of Science:
- Hematology
- Immunology
- Transplantation Medicine
Background:
- Chronic graft-versus-host disease (GVHD) necessitates prolonged immunosuppressive therapy post-hematopoietic cell transplantation.
- Identifying factors influencing immunosuppression duration is crucial for optimizing patient management.
Purpose of the Study:
- To retrospectively analyze characteristics associated with the duration of immunosuppressive treatment in patients with chronic GVHD.
- To identify risk factors for prolonged treatment and their impact on non-relapse mortality.
Main Methods:
- Retrospective analysis of 751 patients diagnosed with chronic GVHD.
- Multivariable modeling to identify predictors of immunosuppressive treatment duration and non-relapse mortality.
Main Results:
- Median treatment duration was 23 months for patients discontinuing therapy after chronic GVHD resolution.
- Prolonged treatment was associated with peripheral blood stem cell grafts, male recipients with female donors, HLA mismatching, hyperbilirubinemia, and multiple affected sites.
- Non-relapse mortality risk increased with HLA mismatching, hyperbilirubinemia, older age, older donors, low platelet counts, and progressive onset, though prednisone dose modified the latter.
Conclusions:
- Specific clinical and biological factors predict longer immunosuppressive treatment durations in chronic GVHD.
- Certain risk factors for prolonged treatment, such as HLA mismatching and hyperbilirubinemia, are also associated with increased non-relapse mortality.
Abstract:
Chronic graft-versus-host disease (GVHD) requires long-term immunosuppressive therapy after hematopoietic cell transplantation. We retrospectively analyzed a cohort of 751 patients with chronic GVHD to identify characteristics associated with the duration of immunosuppressive treatment. Among the 274 patients who discontinued immunosuppressive therapy after resolution of chronic GVHD before recurrent malignancy or death, the median duration of treatment was 23 months. Results of a multivariable model showed that treatment was prolonged in patients who received peripheral blood cells, in male patients with female donors, in those with graft-versus-host HLA mismatching, and in those with hyperbilirubinemia or multiple sites affected by chronic GHVD at the onset of the disease. Nonrelapse mortality was increased among patients with HLA mismatching or hyperbilirubinemia but not among those with other risk factors associated with prolonged treatment for chronic GVHD. Nonrelapse mortality was also increased in older patients and those with older donors, in patients with platelet counts less than 100 000/microL or progressive onset of chronic GVHD from acute GVHD, and in those receiving higher doses of prednisone immediately before the diagnosis of chronic GVHD. After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
01:29Acute Kidney Injury III: Clinical Manifestations
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents